Urologic research and COVID-19: Unmasking the silver lining
In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
Survey: New NMIBC treatments face slow uptake